Kannalife, Inc. is a biopharmaceutical company specializing in the research and development of next-generation cannabinoid-based therapeutics. The company focuses on creating potent, non-opioid alternatives to address significant unmet medical needs, particularly in the areas of neurodegeneration, oxidative stress, and neuropathic pain. Kannalife serves patients with serious medical conditions who require innovative treatment options. Operating in the biopharmaceutical market, Kannalife employs a business model centered on intellectual property and proprietary technology. The company generates revenue through the development and commercialization of its patented cannabinoid molecules, which are designed to be more potent, bioavailable, and safer than traditional CBD products. Kannalife's advancements are supported by a robust portfolio of global patents and ongoing collaborations with leading medical institutions.

Keywords: cannabinoid therapeutics, neurodegeneration, oxidative stress, neuropathic pain, biopharmaceutical, non-opioid, intellectual property, patented molecules, medical research, innovative treatments.